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  The term ‘disorders of sex development’ (DSD) has 
been defined as ‘congenital conditions in which the de-
velopment of chromosomal, gonadal, or anatomical sex is 
atypical’ [Hughes et al., 2006]. DSD covers a wide spec-
trum of phenotypes. 46,XY DSD includes 46,XY com-
plete or partial gonadal dysgenesis, or undervirilisation 
or undermasculinisation of an XY male due to defects in 
androgen synthesis or action. 46,XX DSD includes go-
nadal dysgenesis, or more commonly overvirilisation or 
masculinisation of an XX female due to androgen excess. 
O v o t e s t i c u l a r  D S D  r e f e r s  t o  a n  i n d i v i d u a l  w i t h  b o t h  
ovarian and testicular material present in the same or dif-
ferent gonads, and 46,XX testicular DSD refers to an XX 
male with testes. Other forms of DSD include cloacal ex-
trophy, severe hypospadias, vaginal atresia, and as part
of other conditions such as Mayer-Rokitansky-Kuster-
Hauser syndrome, Smith-Lemli-Opitz syndrome or geni-
to-palato-cardiac syndrome [Porter, 2008; Sultan et al., 
2009]. Although there have been considerable advances 
in our understanding of the genetic factors involved in 
gonadal differentiation in the last 20 years (  fig. 1  ), it has 
been estimated that a molecular diagnosis is made in only 
around 20% of DSD, except in cases where the biochemi-
cal profile indicates a specific steroidogenic block [Hughes 
et al., 2006].
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 Abstract 
  Although the genetic basis of human sexual determination 
and differentiation has advanced considerably in recent 
years, the fact remains that in most subjects with disorders 
of sex development (DSD) the underlying genetic cause is 
unknown. Where pathogenic mutations have been identi-
fied, the phenotype can be highly variable, even within fam-
ilies, suggesting that other genetic variants are influencing 
the expression of the phenotype. This situation is likely to 
change, as more powerful and affordable tools become 
widely available for detailed genetic analyses. Here, we de-
scribe recent advances in comparative genomic hybridisa-
tion, sequencing by hybridisation and next generation se-
quencing, and we describe how these technologies will have 
an impact on our understanding of the genetic causes of 
DSD.    Copyright © 2010 S. Karger AG, Basel 
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    Identification of Novel Genetic Factors by 
Comparative Genomic Hybridisation 
  Comparative genomic hybridisation (CGH) was first 
described in 1992 as an approach to interrogate cancer 
genomic DNA using metaphase chromosomes as probes 
[Kallioniemi et al., 1992]. The strategy of the technique 
was to differentially label the DNA isolated from a test 
and reference cell population with different fluoro-
chromes and to cohybridise the labelled samples to a 
metaphase spread from a reference cell. The relative hy-
bridisation intensity of the test and reference signals at a 
given location is then proportional to the relative copy 
number of those sequences in the test and reference ge-
nomes. If the reference genome is normal, then increases 
and decreases in the intensity ratio directly indicate DNA 
copy number variation in the genome of the test cells. The 
ratio of the intensities of the 2 fluorochromes reflects the 
copy number differences between the cells of interest and 
the control cells.
    The major technical challenge of array CGH is the 
generation of hybridisation signals that are sufficiently 
intense, specific and quantitative so that copy number 
changes can be accurately and reliably detected. In the 
late 1990s, array CGH was first developed by spotting 
DNA from large-insert clones such as BACs (bacterial 
artificial chromosomes) and cDNAs onto microarray 
slides [Solinas-Toldo et al., 1997; Pinkel et al., 1998]. Ar-
ray elements made from genomic BAC clones (complex-
ity 100–200 kb) typically provide more intense signals 
than do elements with shorter sequences such as oligo-
nucleotides, so could be analysed by early detection sys-
tems. However, the advantage of smaller array elements, 
such as oligonucleotides is the much higher genomic res-
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  Fig. 1.  The molecular and genetic events in mammalian sex deter-
mination and differentiation. The bipotential genital ridge is es-
tablished by several genes including  NR5A1  [Wilhelm et al., 2007; 
Sekido and Lovell-Badge, 2009]. In the XY gonad the activation of 
  SRY   expression, possibly initiated by GATA4/FOG2/NR5A1/
WT1, leads to the upregulation of   SOX9   expression via a synergy 
with NR5A1 [Sekido and Lovell-Badge 2008, 2009]. In the XX go-
nad, the supporting cell precursors accumulate     -catenin in re-
sponse to RSPO1/WNT4 signalling and repress   SOX9   activity 
[Schlessinger et al., 2010]. Once SOX9 levels reach a critical thresh-
old, several positive regulatory loops are initiated, including au-
toregulation of its own expression and formation of feed-forward 
loops via FGF9 or PGD2 signalling [Sekido and Lovell-Badge, 
2009]. At later stages, FOXL2 may repress  Sox9  expression [Uhlen-
haut et al., 2009]. In the testis, SOX9 promotes the testis pathway, 
including Amh activation, and it also probably represses the ovar-
ian genes  Wnt4  and  Foxl2  [Sekido and Lovell-Badge, 2009; Uhlen-
haut et al., 2009; Schlessinger et al., 2010].   DMRT1   controls sex 
determination in some species of fish and may be the master sex-
determining switch in birds, but its role in mammalian sexual 
development is unclear [Wilhelm et al., 2007; Smith et al., 2009]. 
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olution (often   !  100) if measurement precision can be 
maintained. The most recent advancement in CGH mi-
croarrays has been the use of oligonucleotide sequences 
as probes [Lucito et al., 2003] ( fig. 2 ) and the development 
of genotyping arrays from low-resolution SNP ( single 
nucleotide polymorphism) arrays to high-resolution hy-
brid arrays that integrate both SNP and CNV (copy 
n u m b e r  v a r i a t i o n )  p r o b e s  [ B i g n e l l  e t  al . ,  2 0 0 4 ] .  N o w  
many different oligoarray platforms are available for 
CGH analyses from various companies including Nim-
blegen (www.nimblegen.com) and Agilent (www.agi-
lent.com) with ever increasing levels of resolution. In ad-
dition, several recent Next Generation Sequencing (NGS) 
approaches also provide information on structural vari-
ation (see below).
    The recent impact of these technologies on medical 
genetics has been substantial [Zhang et al., 2009]. These 
advances include the detection of subtle changes in chro-
mosome architecture associated with cancers [Berou-
khim et al., 2010], severe developmental delay [Girirajan 
et al., 2010], epilepsy [de Kovel et al., 2010], and schizo-
phrenia [Glessner and Hakonarson, 2009]. Like many de-
velopmental processes, human sex development is sensi-
tive to gene dosage effects, and duplication and deletion 
events in the human genome are associated with DSD. 
For example, deletions of terminal 9p24 are associated 
with varying degrees of 46,XY gonadal dysgenesis in 
around 70% of XY individuals with this chromosomal 
change [Barbaro et al., 2009]. A number of reports have 
described deletions of terminal 10q associated with 46,XY 
gonadal dysgenesis together with somatic anomalies. The 
gene responsible for the gonadal phenotype remains un-
identified although   EMX2   has been suggested as a likely 
candidate [Ogata et al., 2000]. Deletions and duplications 
of chromosome 22q11.2 have been described in 3 cases of 
46,XX   SRY  -negative testicular DSD [Aleck et al., 1999; 
Erickson et al., 2003; Seeherunvong et al., 2004]. A micro-
duplication of chromosome 17q, including the  SOX9  gene 
has been reported in a 46,XX man with ambiguous exter-
nal genitalia and otherwise unremarkable phenotype 
[Huang et al., 1999]. Deletion of the dosage sensitive gene 
  NR0B1  , encoding DAX1 on chromosome Xp21.2 results 
in congenital adrenal hypoplasia (AHC), whereas an 
  NR0B1  duplication in 46,XY individuals leads to gonadal 
dysgenesis and a female phenotype [Bardoni et al., 1994]. 
Duplications of   NR0B1   gene have been described in a 
small number of other cases of 46,XY gonadal dysgenesis. 
Duplication of 1p has also been associated with 46,XY 
gonadal dysgenesis although the gene(s) responsible is 
not known [Wieacker and Volleth, 2007].
  CGH analysis is beginning to reveal novel rearrange-
ments associated with 46,XY and 46,XX DSD. This ap-
proach has been used to physically map translocation 
breakpoints in a case of 46,XX ovotesticular DSD asso-
ciated with a 12;17 translocation upstream of the   SOX9  
gene [Refai et al., 2010]. An inherited 960 kb deletion, 
positioned 517 kb to 1.477 Mb upstream of the   SOX9  
gene, was detected by oligoarray CGH in a XY DSD 
child with acampomelic dysplasia and in her affected 
mother [Lecointre et al., 2009]. In both these examples, 
the rearrangements may have lead to the deregulation of 
  SOX9   expression. A large 3 Mb deletion of 9q34 that in-
cludes the   LMX1B   and   NR5A1   genes was identified us-
ing an array CGH approach in a 46,XY girl with clinical 
features of genitopatellar syndrome and ovotesticular 
DSD [Schlaubitz et al., 2007]. More recently a smaller 
970 kb deletion that included the  NR5A1  gene (encoding 
steroidogenic factor-1) was also detected in a 46,XY 
DSD girl without skeletal features [van Silfhout et al., 
2009]. CGH analysis has also been used to define dele-
tions on 11p13 and 9p24 associated with syndromic 
forms of 46,XY DSD [Le Caignec et al., 2007; Vinci et 
al., 2007].
  CGH has successfully identified duplications of  NR0B1  
associated with 46,XY complete gonadal dysgenesis in 
the absence of somatic anomalies [Barbaro et al., 2007] 
and a unique 257 kb deletion located 250 kb upstream of 
  NR0B1   in a 21-year-old girl with 46,XY complete gonad-
al dysgenesis [Smyk et al., 2007]. This deletion presum-
ably results in deregulation of   NR0B1   expression.
    Aside from the detection of subtle rearrangements of 
genetic factors known to be involved in gonadal determi-
nation and differentiation, CGH analyses offer the pos-
sibility to detect new genes involved in these processes. 
CGH analyses revealed a novel recurrent 15q24 microde-
letion syndrome (1.7–3.9 Mb in size) that is characterised 
by growth retardation, microcephaly, digital abnormali-
ties, characteristic facial dysmorphia (high anterior hair 
line, broad medial eyebrows, hypertelorism, downslant-
ed palpebral fissures, broad nasal base, long smooth 
  philtrum and full lower lip), and genital anomalies in
the male (micropenis/hypospadias) [Sharp et al., 2007; 
Andrieux et al., 2009].
    As increasing numbers of subjects with DSD are un-
dergoing analysis using CGH platforms, more pathogen-
ic rearrangements will be reported that may reveal unique 
insights into the mechanism of gonadal somatic cell fate 
determination and development. Bashamboo   /Ledig   /Wieacker   /
Achermann    /McElreavey    
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  Fig. 2.   CGH analysis of a de novo Y chromosome deletion associ-
ated with 46,XY gonadal dysgenesis.   A   This case was first pub-
lished almost 20 years ago and the deletion was detected and the 
extent of the deletion mapped by Southern blotting [McElreavy et 
al., 1992b].   B   The same deletion identified by CGH analysis using 
a Y chromosome-specific platform (www.nimblegen.com). The 
genome profile of the patient versus normal male reference ge-
nomic DNA is shown for the short arm of the Y chromosome. The 
x-axis coordinates indicate the relative position of the oligo probes 
ordered by genomic map position on the Y chromosome. The y-
axis shows the log2 ratio shift. The top panel shows window aver-
aging of signals in 300 bp segments. The middle panel shows the 
normalized signal profile using qspline normalisation. The lower 
panel indicates the genomic position of transcripts on this region 
of chromosome Yp.   New Technologies for DSD   Sex  Dev   2010;4:213–224  217
    Identification of Novel Genetic Factors Associated 
with DSD by Custom Array Sequencing 
  Diagnostic sequencing of genes known to be respon-
sible for DSD using conventional Sanger sequencing is 
useful to identify novel mutations associated with gonad 
development and it is the mainstay of most diagnostic 
laboratories. However, this approach is both time-con-
suming and laborious. High-throughput, high-density 
sequencing using microarray technology offers the pos-
sibility of rapidly and accurately sequencing portions of 
the genome at reduced costs. Several next-generation se-
quencing technologies are emerging (see below) for whole 
genome analyses but at present the costs and considerable 
data handling that are involved means that these ap-
proaches will be limited to the research environment for 
the foreseeable future. In contrast, sequencing by hybri-
disation is suitable for situations in which a moderate 
amount of sequence is being analysed (10–300 kb, repre-
senting several to tens of genes) in a repetitive manner.
    The principle of oligo-hybridisation sequencing is 
based on the differential hybridisation of target DNA to 
an array of oligonucleotide probes, thereby decoding its 
primary DNA sequence. This is most applicable to disor-
der-specific studies such as DSD where sequences can be 
compared with an established reference. CustomSeq ar-
rays developed by Affymetrix rely on allele-specific hy-
bridisation for determining the DNA sequence of interest 
and a single array can be used to sequence up to 300 kb 
of double-stranded unique DNA sequence. Every base to 
be sequenced is represented by probes that are 25 bp long 
and differ only at a single central position [Lipshutz et al., 
1999]. The array uses 4 oligomers per base for each of the 
2 DNA strands. The 4 oligomers differ at a single central 
position that could be A, C, G, or T, and they query com-
plementary bases on the DNA strand. The remaining 24 
positions are the same for all 4 oligomers and are comple-
mentary to the reference DNA sequence being queried.
  Sufficient DNA must be generated for hybridisation to 
the microarray. Current protocols for target-enriched pa-
tient material use locus-specific long-range PCR amplifi-
cation of regions of interest. Long-range PCR minimises 
the number of reactions required, but genes at multiple 
loci, with highly dispersed exons, will require many PCR 
reactions. Long-range PCR products also usually require 
quantification and normalisation prior to hybridisation 
( fig. 3 ). The PCR products are then pooled and fragment-
ed. The DNA fragments are labelled with biotin and sub-
sequently hybridised with the microarray. Finally, the 
microarray is washed, stained and scanned to measure 
the fluorescence intensities (  fig. 3  ). Software, such as the 
G e n e C h i p  S e q u e n c e  A n a l y s i s  S o f t w a r e  ( G S E Q ;  w w w .
affymetrix.com) allows the user to perform sequence 
analysis of the data to produce the final sequence calls.
    Although relatively cheap, sequencing by hybridisa-
tion does have the major drawback of false positive calls. 
These can arise through various mechanisms such as 
PCR failure or SNP interference. The latter occurs when 
2 variants are very close together on the same patient 
DNA fragment. If there is a homozygous variant, the per-
formance of neighbouring probes, which assume a wild-
type base at the variant position, can be poor. Therefore, 
clusters of SNP calls (i.e. SNPs within 9 bases of each oth-
er) should be interpreted with caution. Cross-hybridisa-
tion is a cause of false positives, so a single array cannot 
analyse homologous loci. Repetitive sequences can also 
generate false positive data, although algorithms have 
been developed to improve base call reading.
    The elimination of false positive calls is essential to 
reduce the need to perform confirmatory capillary rese-
quencing. Computational algorithms can be developed 
for specific arrays so that for the detection of rare muta-
tions in clinical disease settings such as DSD, the use of 
an algorithm that compares a single patient data set to 
Genomic DNA
Long-range PCR
DNA fragmentation
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Scan microarray
  Fig. 3.   Schematic overview of procedure involved in sequencing 
b y   h y b r i d i s a t i o n .       Bashamboo   /Ledig   /Wieacker   /
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data from a group of controls is likely to improve call rates 
and false positive rates through a statistical comparison 
of signal strength for each probe. Algorithms may also 
help to solve another problem confronted by array se-
quencing technologies, the detection of novel insertion or 
deletion mutations. However, monoallelic deletions that 
are larger than a PCR amplicon could be missed due to 
the normalisation of PCR products prior to hybridisa-
tion.
    Despite these disadvantages, custom sequencing ar-
rays offer a high-throughput sequencing method that is 
efficient, fast, automatable, and cost-effective for repeti-
tive resequencing of targeted regions of DNA. Relatively 
few examples of this approach have been reported in the 
literature to date. A microarray-based sequencing plat-
form technology to detect sequence alterations in multi-
ple autosomal recessive retinal disease genes was report-
ed with a 99% accuracy and reproducibility [Mandal et 
al., 2005]. A 16 gene sequencing array has recently been 
described for studying genetic variation in genes involved 
in angiogenesis that had a 99.4% sequencing accuracy 
compared with Sanger capillary sequencing [Szoke et al., 
2009]. Similarly, a comparison of 93 worldwide mito-
chondrial genomes sequenced using either the Affyme-
trix GeneChip Human Mitochondrial Resequencing Ar-
ray 2.0 (MitoChip v.2.0) or Sanger sequencing an average 
call rate of 99.48% and an accuracy of 99.98% for the Mi-
toChip [Hartmann et al., 2009]. The failure to detect 
some variants was largely due to the inherent difficulty of 
the array to detect insertions and deletions.
    Identification of Novel Genetic Factors by Next 
Generation Sequencing 
 The advent of next generation sequencing (NGS) tech-
nologies has tremendously reduced the sequencing cost 
and experimental complexity. NGS technologies also of-
fer improved template coverage, rendering sequencing-
based genome analysis more readily available and useful 
to individual laboratories. These sequencing methods 
employ massively parallel approaches to sequence several 
hundred thousand to millions of reads simultaneously 
[Ansorge, 2009; Metzker, 2010].
    The current approaches to NGS falls broadly into 2 
types – polymerase based and ligase based [Ansorge, 
2009; Metzker, 2010]. The recent use of ligases for mas-
sively parallel short-read DNA sequencing of human ge-
nomes offers several unique attributes compared to poly-
merases [Valouev et al., 2008]. In the context of mutation 
detection, the most important difference is the use of an 
error-correcting probe-labelling scheme (two-base en-
coding, or 2BE), which provides error correction concur-
rent with the color-called alignment of the data (i.e. with-
out having to resequence the reads). There are currently 
4 commercially available new-generation sequencing 
technologies. These are the polymerase based systems of 
Roche/454, Illumina/Solexa, Helicos HeliScope and the 
ligase-based Applied Biosystems SOLiD [Margulies et al., 
2005; Bentley et al., 2008; Harris et al., 2008; Valouev et 
al., 2008]. All of these systems produce an abundance of 
short reads at a much higher throughput than is achiev-
Table 1.   Next generation sequencing approaches
Platform Sequencing 
chemistry
Read length 
(bases)
Gb per
run
Run time (frag-
ment library)
System raw
accuracy
Consensus base
accuracy
Disadvantages
Roche/454 GS
FLX titanium
Polymerase 400 0.4–0.6 10 h 99% to
400 bases
99.99% at
15! coverage
Prone to sequence error in
homopolymer DNA sequences
Cost per run expensive.
Illumina/
Solexa GAII
Polymerase 75–100 20a 4 days 98–99% >99.999% at
20! coverage
Low multiplexing capabilities
Life Technologies, 
ABI SOLiD 3+
Ligase 50 60b 12 days 99.94% >99.999% at
15! coverage
Duration of run
Helicos
Biosciences,
Heliscope
Polymerase 32 21 8 days 93–97% 99.995% at
20! coverage
Higher error rates
a  Paired end sequences. The new Illumina/Solexa HiSeq 2000 generates up to 200 Gb per run.b The recent SOLiD  TM  4 System gen-
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able with the state-of-the-art Sanger sequencer and
each have their own unique properties (  table 1  ; see also 
http://www.wellcome.ac.uk/Education-resources/Teach-
ing-and-education/Animations/DNA/index.htm). Other 
NGS approaches are on the horizon. These include nano-
pore sequencing, where individual nucleic acid strands in 
solution are electrophoretically driven through nano-
pore-based devices. The narrow pore can ensure that the 
sequence of nucleic acids can be analysed in their native 
order without the need for prior amplification or label-
ling, therefore resulting in increased accuracy and re-
duced sequencing costs [Branton et al., 2008].
  In NGS, the sequencing is only a part of the entire pro-
cess that includes template preparation, the sequencing 
reaction itself and the data handling and analyses [Med-
vedev et al., 2009; McPherson, 2009; Metzker, 2010]. The 
latter may in fact be more expensive than the costs in-
volved in generating the billions of base pairs of sequence. 
Considerable challenges remain in terms of data transfer, 
storage and quality control. Specialised computational 
analysis and skill are required to align or assemble read 
data, along with laboratory information management 
systems for sample tracking and process management 
[McPherson, 2009].
    DNA template for NGS is achieved either by solution-
based hybridisation strategies or by solid phase amplifi-
cation [Vogelstein, 2003; Fedurco et al., 2006]. In emul-
sion PCR (emPCR), a library of targets is created, and 
adaptors containing universal priming sites are ligated to 
the target ends, allowing complex genomes to be ampli-
fied with common PCR primers. After ligation, the DNA 
is separated into single strands and captured onto beads 
under conditions that favour one DNA molecule per 
bead. After the successful amplification and enrichment 
of emPCR beads, millions can be immobilised in a poly-
acrylamide gel on a standard microscope slide, chemi-
cally crosslinked to an aminocoated glass surface, or
deposited into individual PicoTiterPlate (PTP) wells 
(Roche/454) in which the NGS chemistry can be per-
formed [Leamon, 2003; Metzker, 2010].
    Solid-phase amplification can also be used to pro-
duce randomly distributed, clonally amplified clusters 
from fragment or mate-pair templates on a glass slide. 
High-density forward and reverse primers are covalent-
ly attached to the slide, and the ratio of the primers to 
the template on the support defines the surface density 
of the amplified clusters. Solid-phase amplification can 
produce 100–200 million spatially separated template 
clusters (Illumina/Solexa), providing free ends to which 
a universal sequencing primer can be hybridised to ini-
tiate the NGS reaction. The Helicos BioSciences, Heli-
Scope system is also based on polymerase sequencing-
by-synthesis of single molecules in which labelled DNA 
bases are sequentially added to the nucleic acid tem-
plates captured on a flow cell (http://www.helicosbio.
com). No prior amplification process is involved in this 
system resulting in a non-bias representation of tem-
plates for genome sequencing, although the error rate 
may be higher than other polymerase-based systems 
[Harris et al., 2008].
    The Roche 454 system uses pyrosequencing technol-
ogies to enable the simultaneous sequencing of several 
hundred thousand DNA fragments, with a read of 400 
b p  ( www . 4 5 4 . c o m ) .  Pyr o s e q u e n c in g  i s  a  b i o l umin e s -
cence method that measures the release of inorganic py-
rophosphate into a synthesised DNA strand by convert-
ing it into visible light by a series of enzymatic reactions 
[Ronaghi et al., 1996]. The order and intensity of the 
generated light is detected and recorded in the form of 
a peak signal, which reveals the underlying DNA se-
quence. The Illumina (Solexa) Genome Analyzer (GA) 
uses sequencing-by-synthesis to generate    200  million 
75–100-bp reads (http://www.illumina.com/systems/
genome_analyzer .ilmn ) . This is a cy clic method that 
comprises nucleotide incorporation, fluorescence imag-
ing and cleavage. In the first step, a DNA polymerase, 
bound to the primed template, adds or incorporates just 
one fluorescently modified nucleotide, which represents 
the complement of the template base. The termination 
of DNA synthesis after the addition of a single nucleo-
tide is an important feature of this approach. Following 
incorporation, the remaining unincorporated nucleo-
tides are washed away. Imaging is then performed to 
determine the identity of the incorporated nucleotide. 
This is followed by a cleavage step, which removes the 
terminating/inhibiting group and the fluorescent dye. 
Additional washing is performed before starting the 
next incorporation.
    A novel massively parallel sequencing technology 
based on ligation of oligonucleotides as opposed to se-
quencing by synthesis has been developed by Applied 
Biosystems (http://solid.appliedbiosystems.com). In this 
approach, sequencing is carried out via sequential rounds 
of probe annealing and ligation with high fidelity and 
high read quality (  fig. 4  ). Sequence errors are consider-
ably reduced compared to polymerase-based systems be-
cause the ligation method is based on probe recognition 
rather than sequential nucleotide addition. In this sys-
tem, there are 16 dinucleotide combinations with 4 fluo-
rescent dyes, each dye corresponding to a probe pool of 4  Bashamboo   /Ledig   /Wieacker   /
Achermann    /McElreavey    
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dinucleotides per pool (  fig. 4  ). Using this dinucleotide, 
4-dye encoding scheme in conjunction with a sequencing 
assay that samples every base, each base is effectively 
probed by 2 different and independent reactions. The 
double interrogation of each base causes a true SNP poly-
morphism to result in a 2 consecutive colour change 
while a measurement error results in a single colour 
change. The SOLiD  TM  (Sequencing by Oligo Ligation and 
Detection) platform is capable now of producing 400 mil-
lion 50-bp reads (combined total in 2 independent flow 
cells). This approach essentially eliminates the possibility 
of spurious insertions or deletions.
  Recently, the SOLiD system has been used to assay nu-
cleotide variation in HapMap samples, in the framework 
of the 1000 Genomes Project [McKernan et al., 2009]. The 
1000 Genomes Project is a collaboration among research 
groups in the US, UK, China, and Germany to produce 
an extensive catalogue of human genetic variation that 
will support future medical research studies (www.
1000genomes.org). It will extend the data from the Inter-
national HapMap Project and will allow genome-wide as-
sociation studies to focus on almost all variants that exist 
in regions found to be associated with disease. The ge-
nomes of over 1,000 unidentified individuals from around 
the world will be sequenced using next generation se-
quencing technologies. Three HapMap samples were se-
quenced via the ligation-based approach utilised in the 
SOLiD sequencing system [McKernan et al., 2009]. In one 
sample with a sequence coverage estimated at 29  ! ,  97% 
of heterozygotes SNPs and 99.96% of homozygotes SNPs 
were detected and false discovery rate was negligible 
[McKernan et al., 2009].
  This approach is particularly useful for variation dis-
covery in genetic association studies, where low se-
quence coverage (5  !  ) and therefore lower cost, may de-
tect a significant portion of the total sequence variation. 
To detect pathogenic mutations associated with disease 
a higher coverage is needed. What is the required accu-
racy for mutation discovery? A single base pair change 
may result in a DSD phenotype and any error in se-
quencing can give rise to false positives or false nega-
tives, leading to time-consuming and challenging 
downstream studies. The raw sequencing accuracy is 
the accuracy of a single-pass sequencing read. This is an 
excellent measurement of each method’s chemistry, flu-
orescence readout, process, and base-calling software 
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Adapter sequence Template
5’
3’
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3’
Bead
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3’ *
3’ * 3’ *
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G A * C-T-n-n-n
G A
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P5’
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Ligate
G-A-n-n-n A-G-n-n-n
C-C-n-n-n
C-T-n-n-n
C-T-n-n-n
  Fig. 4.   Schematic representation of 
SOLiD  TM   sequencing by ligation. Primers 
hybridise to the P1 adapter within the li-
brary template. A set of 4 fluorescence-la-
belled di-base probes competes for ligation 
to the sequencing primer. These probes 
have partly degenerated DNA sequence 
(indicated by n) and for simplicity only one 
probe is shown (labelling is denoted by as-
terisk). The specificity of the di-base probe 
is achieved by interrogating every 1st and 
2nd base in each ligation reaction. Multi-
ple cycles of ligation, detection and cleav-
age are performed with the number of cy-
cles determining the eventual read length 
(modified from http://www3.appliedbio-
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(  table 1  ). Ultimately, the more robust the raw reads, the 
fewer redundant reads are required, keeping the overall 
costs down. At the time of writing, the SOLiD system 
shows a high degree of sequence accuracy, even at low 
coverage, and this may be the system of choice for muta-
tion detection.
    Overall substantial cost reductions are associated 
with NGS technologies when compared with the Sanger 
method, but sequencing the whole human genome re-
mains expensive for most laboratories. In the search for 
novel genetic markers of DSD, the medium term may see 
a more targeted approach. Specific regions of the ge-
nome may be enriched for sequencing: for example, se-
quencing all of the exons in the genome; sequencing 
specific gene families of interest; or focusing just on 
large chromosome regions or entire chromosomes that 
are implicated in disease. Exome capture approaches are 
available for targeting approximately 33 Mb or   180,000 
coding exons across the human genome. Many plat-
forms also offer capture of miRNAs and non-coding 
RNA sequences. Selective genomic enrichment of the 
human exome offers an attractive option for devising 
new experimental designs aimed at quick identification 
of potential disease-associated genetic variants. Human 
exome capture methods are currently based on either 
custom-designed oligonucleotide microarrays or solu-
tion-based hybridisation strategies. Roche/Nimblegen 
offers microarray capture platforms for solid phase hy-
bridisation for the enrichment of exons [Albert et al., 
2007]. The reported capture efficiency for these plat-
forms ranges from 50–90% [Hodges et al., 2007]. Solu-
tion-based hybridisation methods for exon capture, 
such as molecular inversion probes (mIPs) [Porreca et 
al., 2007; Turner et al., 2009] and biotinylated RNA cap-
ture sequences [Gnirke et al., 2009; SureSelect Human 
All Exon Kit; Agilent Technologies] have also been de-
veloped that have capture efficiencies of 70–90%. Rain-
dance technologies (www.raindancetechnologies.com) 
offers targeted sequence enrichment using a microflu-
idic device to create aqueous picolitre-volume droplets 
of forward- and reverse-targeting primers in an oil solu-
tion [Tewhey et al., 2009]. In a microfluidic chip, the 
primer pair droplets and template droplets, which con-
tain fragmented genomic DNA and PCR reagents, are 
paired together in a 1:     1 ratio. An electric field induces 
the 2 droplets to merge into a single PCR droplet. Around 
1.5 million PCR droplets can be collected in a single 
PCR tube. This approach has been reported to have an 
84% capture efficiency with 90% of the targeted bases 
showing uniform coverage when sequenced with either 
the Roche/454 or Illumina/Solexa platform [Tewhey et 
al., 2009]. From a medical perspective, this approach is 
interesting since it is particularly suitable for working 
with cells of limited availability, such as stem cells or 
primary cells from patients [Brouzes et al., 2009].
    NGS with exome capture has recently been applied to 
identify mutations associated with mendelian disorders 
[Ng et al., 2009, 2010]. Using Freeman-Sheldon syndrome 
(FSS) as a proof-of-concept, Ng and colleagues performed 
exome enrichment and sequencing using the Illumina 
system to identify the causal mutation for FSS. The same 
group has recently identified mutations in the   DHODH  
gene in 4 individuals from 3 pedigrees with Miller syn-
drome (postaxial acrofacial dysostosis) using exome se-
quence capture and sequencing to a coverage of 40 !  with 
sufficient depth to call variants at approximately 97% of 
each targeted exome.
    In addition, the recent NGS applications not only 
have the ability to generate huge amounts of sequence 
data but they also reveal structural variation, thereby 
bypassing the need for CGH analyses [McKernan et al., 
2009].
  These recent studies show the power of NGS approach-
es to detect pathogenic mutations causing disease. This 
approach also offers the opportunity to identify genetic 
modifiers. Familial cases of both 46,XY and 46,XX DSD 
often show considerable variation in the expression of the 
phenotype, including families where the underlying ge-
netic mutation has been identified [Lourenco et al., 2009; 
Temel et al., 2007]. This phenotypic variability may be 
explained by variations in other genes that may interact 
with or influence the activity of the target gene. This has 
been shown in a pedigree with hypogonadotropic hypo-
gonadism, where a compound heterozygous  GNRHR  and 
a heterozygous   FGFR1   mutation were identified [Pittel-
oud et al., 2007].
    When considering these NGS approaches that are 
currently costly and require considerable bioinformatics 
analyses, an important question to pose is what would be 
the cost benefits to the DSD field? The usefulness of this 
non-a priori approach to identify genetic modifiers has 
been mentioned above, but are there new genetic factors 
that when mutated could cause DSD? The reply to this 
question is yes. For example, almost all cases of non-syn-
dromic ovotesticular DSD remain unexplained although 
there have been considerable genetic analyses of candi-
date genes [McElreavey et al., 1992a; Temel et al., 2007]. 
Despite advances in understanding the mechanisms of 
mammalian gonad formation, the underlying genetic 
cause of most cases of 46,XY gonadal dysgenesis remains  Bashamboo   /Ledig   /Wieacker   /
Achermann    /McElreavey    
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unknown [McElreavey and Fellous, 1999]. Mutations in 
the androgen receptor (AR) gene are the most common 
genetic cause of 46,XY DSD. However, even in 46,XY 
underandrogenised subjects with testes who are suspect-
ed to have an AR defect, a pathogenic mutation is found 
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et al., 2009]. Recently, a mutation in   Map3k4   was associ-
ated with XY gonadal sex reversal in the mouse, suggest-
ing that mutations in mitogen-activated protein kinase 
(MAPK) signalling pathway may be associated with 
DSD [McElreavey et al., unpublished data; Bogani et al., 
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    It is clear that NGS will have a tremendous impact on 
medicine [ V oelkerding et al., 2009 ] . Exciting develop-
ments are rapidly taking place in the field and these are 
leading to a deeper understanding of variation across in-
dividual genomes, genetic variation in tissues within an 
individual and the identification of disease causing muta-
tions. Sequencing technology is continuing to evolve at 
an unprecedented pace. The generation of massive data 
sets of qualitative and quantitative information of both 
RNA and DNA sequences in a patient sample at a rela-
tively limited cost will transform the field of reproductive 
disorders by offering novel insights into the genetics and 
physiology of DSD.
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Erratum
In the article by Bashamboo et al. ‘New Technologies for the Identification of Novel Ge-
netic Markers of Disorders of Sex Development (DSD)’ (Sex Dev DOI: 10.1159/000314917) 
an error occurred with one of the author names.
Now it reads ‘J. Achermann’ but the correct name is ‘J.C. Achermann’.